Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Mar 2021
Jacinda Ardern responds to heartfelt plea from PHARMAC funding advocate Malcolm Mulholland
8 March 2021 - Prime Minister Jacinda Ardern has responded to a heartfelt plea by Malcolm Mulholland, a man advocating ...
Posted by Michael Wonder on 07 Mar 2021
Primary dyslipidaemia drug Praluent gets insurance benefit
5 March 2021 - Sanofi-Aventis Korea’s primary dyslipidaemia treatment Praluent (alirocumab) has won health insurance benefits, the government said. ...
Posted by Michael Wonder on 07 Mar 2021
‘We can’t do much with 50 doses’: GPs concerned about supply, capability of COVID-19 vaccine
7 March 2021 - With GPs to start vaccinating patients against COVID-19 in two weeks, one doctor in Melbourne’s west ...
Posted by Michael Wonder on 07 Mar 2021
Cancer Society says PHARMAC review doesn't go far enough
3 March 2021 - A review of drug buying agency PHARMAC is being described as long overdue. ...
Posted by Michael Wonder on 07 Mar 2021
PHARMAC does a great job, but it's losing the PR battle hands down
6 March 2021 - With each major change of government in recent years, PHARMAC has been required either to list ...
Posted by Michael Wonder on 07 Mar 2021
Where is the corrigenda?
8 March 2021 - Can the Department of Health simply ignore PBAC advice? ...
Posted by Michael Wonder on 07 Mar 2021
Canada authorises one-shot COVID-19 vaccine from Johnson & Johnson
5 March 2021 - The first one-shot COVID-19 vaccine from Johnson & Johnson has been authorized by Health Canada, making ...
Posted by Michael Wonder on 07 Mar 2021
Australian rollout to include 4,500 GP clinics as it moves to phase 1b
7 March 2021 - Local doctors will be brought in for phase 1b of the rollout, which targets older people ...
Posted by Michael Wonder on 06 Mar 2021
U.S. FDA approves Yescarta for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
5 March 2021 - Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma; approval marks the third ...
Posted by Michael Wonder on 06 Mar 2021
Genentech’s Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis associated interstitial lung disease, a rare, debilitating condition
4 March 2021 - The U.S. FDA previously granted priority review designation to Actemra for the treatment of systemic sclerosis-associated ...
Posted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
Posted by Michael Wonder on 05 Mar 2021
Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
3 March 2021 - The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant ...
Posted by Michael Wonder on 05 Mar 2021
New legislation to support medicine substitutions
5 March 2021 - New legislation has been passed to allow pharmacists to substitute a different medicine when a patient's ...
Posted by Michael Wonder on 05 Mar 2021
PBAC Public Summary Documents - November 2020 meeting
5 March 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2020 PBAC ...
Posted by Michael Wonder on 05 Mar 2021
TGA adopts Access Consortium guidance for fast-tracking authorisations of modified COVID-19 vaccines for variant
5 March 2021 - TGA has adopted guidance developed by the Access Consortium - a coalition of regulatory authorities from ...